These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11810598)

  • 21. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
    Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
    Fisher M
    AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metabolic disorders and lipodystrophy. Adverse effects of antiretroviral therapy].
    Goebel FD; Westner I
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():40-4. PubMed ID: 11373778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
    Moyle G; Carr A
    HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812
    [No Abstract]   [Full Text] [Related]  

  • 30. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
    J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
    Hartman K; Verweel G; de Groot R; Hartwig NG
    Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
    Sattler FR
    Top HIV Med; 2008; 16(4):127-33. PubMed ID: 18838747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipodrama.
    Horn T
    Res Initiat Treat Action; 1999 Dec; 5(5):13-5. PubMed ID: 11366885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal].
    Diouf A; Cournil A;
    Bull Soc Pathol Exot; 2014 Oct; 107(4):234-7. PubMed ID: 24683016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India.
    Kalyanasundaram AP; Jacob SM; Hemalatha R; Sivakumar MR
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):329-34. PubMed ID: 21508297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
    Eriksson LE; Nilsson Schönnesson L; Bratt GA
    Biol Res Nurs; 2011 Jan; 13(1):89-96. PubMed ID: 19942593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipodystrophy in a patient treated with stavudine and didanosine].
    Ruel M; Chemlal K; Melchior JC
    Ann Med Interne (Paris); 1999 Apr; 150(3):269-71. PubMed ID: 10445099
    [No Abstract]   [Full Text] [Related]  

  • 38. Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine.
    Sawawiboon N; Wittawatmongkol O; Phongsamart W; Prasitsuebsai W; Lapphra K; Chokephaibulkit K
    Int J STD AIDS; 2012 Jul; 23(7):497-501. PubMed ID: 22844004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens.
    Lonergan JT; Behling C; Pfander H; Hassanein TI; Mathews WC
    Clin Infect Dis; 2000 Jul; 31(1):162-6. PubMed ID: 10913415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stavudine versus zidovudine and the development of lipodystrophy.
    Bogner JR; Vielhauer V; Beckmann RA; Michl G; Wille L; Salzberger B; Goebel FD
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):237-44. PubMed ID: 11464142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.